# NCT03233711 (NCT03233711)

> Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03233711
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage III Anal Cancer AJCC v8
- Interventions: Biopsy Procedure; Biospecimen Collection; Colonoscopy; Computed Tomography; Digital Rectal Examination; High Resolution Anoscopy; Magnetic Resonance Imaging; Nivolumab; Patient Observation; Proctoscopy; Sigmoidoscopy; X-Ray Imaging
- Enrollment: 344
- Primary outcome: Disease free survival

## Commentary we found

- X threads: 6
- YouTube: 4
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03233711

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03233711", "email": "<work email>"}; the inbox owner confirms by the emailed link.